Item request has been placed!
×
Item request cannot be made.
×
Processing Request
European Commission Approves Gilead Sciences’ Tybost™, a New Boosting Agent for HIV Therapy
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Abstract:
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission has granted marketing authorization for once-daily Tybost™ (cobicistat 150 mg tablets), a pharmacokinetic enhancer that boosts blood levels of certain HIV medicines. Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir 300 mg once daily and darunavir 800 mg once daily as part of antiretroviral combination therapy in adults with HIV-1 infection. Today’s approval allows for the marketing of Tybost in all 28 countries of the European Union (EU). [ABSTRACT FROM PUBLISHER]
No Comments.